These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 9790357)

  • 21. Valacyclovir. New indication: for genital herpes, simpler administration.
    Can Fam Physician; 1999 Jul; 45():1698-700, 1703-5. PubMed ID: 10424269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group.
    Fife KH; Barbarash RA; Rudolph T; Degregorio B; Roth R
    Sex Transm Dis; 1997 Sep; 24(8):481-6. PubMed ID: 9293612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age.
    Kimberlin DW; Jacobs RF; Weller S; van der Walt JS; Heitman CK; Man CY; Bradley JS
    Clin Infect Dis; 2010 Jan; 50(2):221-8. PubMed ID: 20014952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy.
    Beutner KR
    Antiviral Res; 1995 Dec; 28(4):281-90. PubMed ID: 8669888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects.
    DeJesus E; Wald A; Warren T; Schacker TW; Trottier S; Shahmanesh M; Hill JL; Brennan CA;
    J Infect Dis; 2003 Oct; 188(7):1009-16. PubMed ID: 14513421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.
    Perti T; Saracino M; Baeten JM; Johnston C; Diem K; Ocbamichael N; Huang ML; Selke S; Magaret A; Corey L; Wald A
    J Acquir Immune Defic Syndr; 2013 Jun; 63(2):201-8. PubMed ID: 23542637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children.
    Nadal D; Leverger G; Sokal EM; Floret D; Perel Y; Leibundgut K; Weller S
    J Infect Dis; 2002 Oct; 186 Suppl 1():S123-30. PubMed ID: 12353197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial.
    Mugwanya K; Baeten JM; Mugo NR; Irungu E; Ngure K; Celum C
    J Infect Dis; 2011 Dec; 204(12):1912-7. PubMed ID: 21998479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection.
    Bavaro JB; Drolette L; Koelle DM; Almekinder J; Warren T; Tyring S; Wald A
    Sex Transm Dis; 2008 Apr; 35(4):383-6. PubMed ID: 18362859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aciclovir and its l-valyl ester, valaciclovir.
    Smiley ML; Murray A
    Curr Probl Dermatol; 1996; 24():209-18. PubMed ID: 8743272
    [No Abstract]   [Full Text] [Related]  

  • 31. Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection.
    Hollier LM; Wendel GD
    Cochrane Database Syst Rev; 2008 Jan; (1):CD004946. PubMed ID: 18254066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.
    Johnston C; Saracino M; Kuntz S; Magaret A; Selke S; Huang ML; Schiffer JT; Koelle DM; Corey L; Wald A
    Lancet; 2012 Feb; 379(9816):641-7. PubMed ID: 22225814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group.
    Patel R; Bodsworth NJ; Woolley P; Peters B; Vejlsgaard G; Saari S; Gibb A; Robinson J
    Genitourin Med; 1997 Apr; 73(2):105-9. PubMed ID: 9215091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy.
    Yi TJ; Walmsley S; Szadkowski L; Raboud J; Rajwans N; Shannon B; Kumar S; Kain KC; Kaul R; Tan DH
    Clin Infect Dis; 2013 Nov; 57(9):1331-8. PubMed ID: 23946220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on antiviral therapy for genital herpes infection.
    Geers TA; Isada CM
    Cleve Clin J Med; 2000 Aug; 67(8):567-73. PubMed ID: 10946451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infant safety during and after maternal valacyclovir therapy in conjunction with antiretroviral HIV-1 prophylaxis in a randomized clinical trial.
    Drake AL; Roxby AC; Kiarie J; Richardson BA; Wald A; John-Stewart G; Farquhar C
    PLoS One; 2012; 7(4):e34635. PubMed ID: 22509337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2.
    Roxby AC; Drake AL; Ongecha-Owuor F; Kiarie JN; Richardson B; Matemo DN; Overbaugh J; Emery S; John-Stewart GC; Wald A; Farquhar C
    PLoS One; 2012; 7(6):e38622. PubMed ID: 22701683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy.
    Wang LH; Schultz M; Weller S; Smiley ML; Blum MR
    Antimicrob Agents Chemother; 1996 Jan; 40(1):80-5. PubMed ID: 8787884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.
    Nagot N; Ouédraogo A; Foulongne V; Konaté I; Weiss HA; Vergne L; Defer MC; Djagbaré D; Sanon A; Andonaba JB; Becquart P; Segondy M; Vallo R; Sawadogo A; Van de Perre P; Mayaud P;
    N Engl J Med; 2007 Feb; 356(8):790-9. PubMed ID: 17314338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Not Available].
    Sénat MV; Anselem O; Picone O; Renesme L; Sananès N; Vauloup-Fellous C; Sellier Y; Laplace JP; Sentilhes L
    Gynecol Obstet Fertil Senol; 2017 Dec; 45(12):705-714. PubMed ID: 29132768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.